{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-063416","form_type":"8-K","ticker":"KTTA","cik":"0001841330","company_name":"Pasithea Therapeutics Corp.","filed_at":"2022-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.640428+00:00","generated_at":"2026-06-23T04:09:37.213879+00:00","sec_items":["1.01","2.01","3.02","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pasithea acquires AlloMek for $1.05M cash, 2.7M shares + warrants; adds MEK inhibitor CIP-137401","bullets":["Total deal value includes $1.05M cash, 2.7M restricted shares, 1M warrants at $1.88, up to $5M milestones, and royalties.","CIP-137401 is a macrocyclic MEK inhibitor for NF1 and Noonan syndrome; already has FDA orphan-drug designation for NF1.","Plans to file IND in 2H 2023 and initiate Phase 1 trial in NF1; expects synergies with existing MS program.","Daniel Schneiderman appointed CFO effective Oct 11, 2022 with base salary $330K and 300K stock options.","Sellers subject to two-year lock-up; 1.35M shares lock up release at one year, then 112.5K monthly."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-063416","json":"https://secwatch.observer/filing/0001213900-22-063416.json","markdown":"https://secwatch.observer/filing/0001213900-22-063416.md","text":"https://secwatch.observer/filing/0001213900-22-063416.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841330/000121390022063416/0001213900-22-063416-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841330/000121390022063416/ea167014-8k_pasithea.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:09:37.213879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a069729ac","claim":"Daniel Schneiderman was appointed as Chief Financial Officer at Pasithea Therapeutics Corp..","evidence_excerpt":"Effective October 11, 2022, Daniel Schneiderman was appointed to serve as the Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390022063416/0001213900-22-063416-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}